An official website of the United States government
TLC: Indeterminate Liver Nodules
Trial Status: active
This study compares the results of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound (CEUS) for early-stage hepatocellular carcinoma (HCC) or liver cancer detection in patients with indeterminate liver nodules (ILNs).
Inclusion Criteria
* Child A, B, or C cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast-enhanced MRI, or contrast enhanced US but without HCC at baseline.
* Adults 18 years old and above
Exclusion Criteria
* Patients post liver transplantation
* Those with concurrent or prior HCC (LR-5 or biopsy proven) or
* Other liver cancer including cholangiocarcinoma, and
* Patients with any active extra-hepatic malignancy
* Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit.
* Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia
Additional locations may be listed on ClinicalTrials.gov for NCT06184152.
I. Compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound (CEUS) for early-stage HCC detection in patients with ILNs.
OUTLINE: This is an observational study.
Patients undergo AMRI and CEUS, complete a survey, and have their medical records reviewed on study.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUT Southwestern/Simmons Cancer Center-Dallas
